Table 2.

Adverse events leading to discontinuation of the drug

	Adalimumab (n = 17)	Infliximab (n = 13)
Malignant tumor, n	7 (4 lung cancer, 1 colon cancer, 1 prostate cancer, 1 tongue cancer)	1 (1 gastric cancer)
Drug eruption (including suspected cases), n	2	1
Infusion reaction, n	1	2
Interstitial pneumonia, n	2	0
Cerebral infarction, n	1	1
Hypertension, n	0	2
Malaise, n	2	0
Tuberculous lymphadenitis, n	0	1
Acute hepatitis B infection, n	0	1
IgA vasculitis, n	1	0
Thrombocytopenia, n	1	0
Pneumocystis pneumonia, n	0	1
Bacterial pneumonia, n	0	1
Panic attack, n	0	1
Proteinuria, n	0	1
Severe headache, n	0	1